Evidence map›Paper›PMID 27845954›Full record

ArticleCritical care medicine2017

Sulfonylurea Receptor-1: A Novel Biomarker for Cerebral Edema in Severe Traumatic Brain Injury.

Ruchira M Jha, Ava M Puccio, Sherry Hsiang-Yi Chou, Chung-Chou H Chang, Jessica S Wallisch, Bradley J Molyneaux, Benjamin E Zusman, Lori A Shutter, Samuel M Poloyac, Keri L Janesko-Feldman and 2 more

Open access · greenAbstract read
In one paragraph

Article in Critical care medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Glibenclamide for Brain Contusions: Contextualizing a Promising Clinical Trial Design that Leverages an Imaging-Based TBI Endotype.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Sulfonylurea Receptor 1 in Central Nervous System Injury: An Updated Review.International journal of molecular sciences · 2021
    Review
  13. Emerging therapeutic targets for cerebral edema.Expert opinion on therapeutic targets · 2021
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Biomarkers in traumatic brain injury: new concepts.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Ruchira M Jha1Department of Critical Care Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA. 2Department of Neurosurgery, School of Medicine, University of Pittsburgh, Pittsburgh, PA. 3Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, PA. 4Safar Center for Resuscitation Research, School of Medicine, University of Pittsburgh, Pittsburgh, PA. 5Clinical and Translational Science, School of Medicine, University of Pittsburgh, Pittsburgh, PA. 6Department of Biostatistics, School of Medicine, University of Pittsburgh, Pittsburgh, PA. 7Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA. 8Department of Anesthesiology, School of Medicine, University of Pittsburgh, Pittsburgh, PA.
Ava M Puccio
Sherry Hsiang-Yi Chou
Chung-Chou H Chang
Jessica S Wallisch
Bradley J Molyneaux
Benjamin E Zusman
Lori A Shutter
Samuel M Poloyac
Keri L Janesko-Feldman
David O Okonkwo
Patrick M Kochanek
University of Pittsburgh · US

Funding

The Stroke Hyperglycemia Insulin Network Effort (SHINE) TrialU01NS069498 · NINDS · UNIVERSITY OF VIRGINIA · PI BRUNO, ASKIEL, HALL, CHRISTIANA · 2011 to 2017
$27.7M
Institutional Career Development CoreKL2TR001856 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RAY, KRISTIN N, RUBIO, DORIS M · 2016 to 2025
$13.8M
University of Pittsburgh Clinical and Translational Science InstitutionKL2TR000146 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$8.7M
PEDIATRIC NEUROINTENSIVE CARE AND RESUSCITATION RESEARCHT32HD040686 · NICHD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Robert S B Clark, PATRICK M KOCHANEK · 2000 to 2026
$7.1M
Multidisciplinary Training in Critical Care Outcomes ResearchT32HL007820 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Timothy D Girard, Jeremy M Kahn · 1996 to 2026
$6.4M
Developing Goal Directed Perfusion Therapy in SAH Neurocardiac InjuryR01NR014221 · NINR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FRIEDLANDER, ROBERT M., HRAVNAK, MARILYN · 2014 to 2017
$2.2M
Biomarkers of Vasospasm and Outcome following Subarachnoid HemorrhageK23NS073806 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHOU, SHERRY HSIANG-YI · 2011 to 2015
$940k
NCATS NIH HHS KL2 TR000146NCATS NIH HHS KL2 TR001856NHLBI NIH HHS T32 HL007820NICHD NIH HHS T32 HD040686NINDS NIH HHS K23 NS073806NINDS NIH HHS U01 NS069498NINR NIH HHS R01 NR014221
6 · The paper itself

Abstract

objectivesCerebral edema is a key poor prognosticator in traumatic brain injury. There are no biomarkers identifying patients at-risk, or guiding mechanistically-precise therapies. Sulfonylurea receptor-1-transient receptor potential cation channel M4 is upregulated only after brain injury, causing edema in animal studies. We hypothesized that sulfonylurea receptor-1 is measurable in human cerebrospinal fluid after severe traumatic brain injury and is an informative biomarker of edema and outcome.

designA total of 119 cerebrospinal fluid samples were collected from 28 severe traumatic brain injury patients. Samples were retrieved at 12, 24, 48, 72 hours and before external ventricular drain removal. Fifteen control samples were obtained from patients with normal pressure hydrocephalus. Sulfonylurea receptor- 1 was quantified by enzyme-linked immunosorbent assay. Outcomes included CT edema, intracranial pressure measurements, therapies targeting edema, and 3-month Glasgow Outcome Scale score. MAIN

resultsSulfonylurea receptor-1 was present in all severe traumatic brain injury patients (mean = 3.54 ± 3.39 ng/mL, peak = 7.13 ± 6.09 ng/mL) but undetectable in all controls (p < 0.001). Mean and peak sulfonylurea receptor-1 was higher in patients with CT edema (4.96 ± 1.13 ng/mL vs 2.10 ± 0.34 ng/mL; p = 0.023). There was a temporal delay between peak sulfonylurea receptor-1 and peak intracranial pressure in 91.7% of patients with intracranial hypertension. There was no association between mean/peak sulfonylurea receptor-1 and mean/peak intracranial pressure, proportion of intracranial pressure greater than 20 mm Hg, use of edema-directed therapies, decompressive craniotomy, or 3-month Glasgow Outcome Scale. However, decreasing sulfonylurea receptor-1 trajectories between 48 and 72 hours were significantly associated with improved cerebral edema and clinical outcome. Area under the multivariate model receiver operating characteristic curve was 0.881.

conclusionsThis is the first report quantifying human cerebrospinal fluid sulfonylurea receptor-1. Sulfonylurea receptor-1 was detected in severe traumatic brain injury, absent in controls, correlated with CT-edema and preceded peak intracranial pressure. Sulfonylurea receptor-1 trajectories between 48 and 72 hours were associated with outcome. Because a therapy inhibiting sulfonylurea receptor-1 is available, assessing cerebrospinal fluid sulfonylurea receptor-1 in larger studies is warranted to evaluate our exploratory findings regarding its diagnostic, and monitoring utility, as well as its potential to guide targeted therapies in traumatic brain injury and other diseases involving cerebral edema.

Indexed as

AdolescentAdultAgedArea Under CurveBiomarkersBrain EdemaBrain Injuries, TraumaticCase-Control StudiesFemaleGlasgow Coma ScaleGlasgow Outcome ScaleHumansIntracranial PressureMaleMiddle AgedProspective StudiesABCC8 protein, humanBiomarkersSulfonylurea Receptors

Identifiers

PMID27845954
PMCPMC5550829
OpenAlexW2551862508

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.